SI-BONE To Report First Quarter 2023 Financial Results on
SANTA CLARA, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal...
Source: globenewswire.com
Page 11 - Si Bone News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Si Bone. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Si Bone Today - Breaking & Trending Today
SI-BONE, Inc. (NASDAQ:SIBN) Insider Anthony J. Recupero Sells 1,712 Shares
SI-BONE, Inc. (NASDAQ:SIBN – Get Rating) insider Anthony J. Recupero sold 1,712 shares of the business’s stock in a transaction that occurred on Monday, April 3rd. The stock was sold at an average price of $19.28, for a total value of $33,007.36. Following the completion of the sale, the insider now owns 227,815 shares of […]
Source: kopsource.com
SI-BONE, Inc. (NASDAQ:SIBN) CFO Anshul Maheshwari Sells 1,229 Shares of Stock
SI-BONE, Inc. (NASDAQ:SIBN – Get Rating) CFO Anshul Maheshwari sold 1,229 shares of the company’s stock in a transaction dated Monday, April 3rd. The shares were sold at an average price of $19.30, for a total transaction of $23,719.70. Following the completion of the sale, the chief financial officer now directly owns 159,697 shares of […]
Source: themarketsdaily.com
SI-BONE, Inc. (NASDAQ:SIBN) Receives $24.63 Average Target Price from Analysts
SI-BONE, Inc. (NASDAQ:SIBN – Get Rating) has been given a consensus rating of “Buy” by the eight brokerages that are presently covering the firm, MarketBeat reports. Seven investment analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts that have updated their coverage on the stock in the […]
Source: theenterpriseleader.com
SI-BONE, Inc. (NASDAQ:SIBN) Receives Consensus Rating of "Buy" from Analysts
SI-BONE, Inc. (NASDAQ:SIBN – Get Rating) has been assigned an average recommendation of “Buy” from the eight analysts that are presently covering the firm, MarketBeat.com reports. Seven research analysts have rated the stock with a buy rating. The average 12-month price target among analysts that have issued ratings on the stock in the last year […]
Source: wkrb13.com